Targeting DEPTOR in multiple myeloma
Targeting DEPTOR in multiple myeloma
批准号:
9977974
负责人:
ALAN K LICHTENSTEIN
金额:
$28.82万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2022-07-31
关键词:
8q24ApoptosisApoptosis Regulation GeneAutophagocytosisBindingBinding ProteinsBiochemicalCellsCessation of lifeChromosomesClinicComplexCyclin D1DataDiagnosisDiseaseFRAP1 geneFutureGene ExpressionGenetic TranscriptionGlycolysisHybridsLeadMalignant NeoplasmsMolecularMultiple MyelomaMusNormal tissue morphologyParalysedPatientsPentosephosphate PathwayPharmaceutical PreparationsPhosphotransferasesPlayProteasome InhibitorProteinsPublic HealthRegulationResistanceRoleTP53 geneTestingTherapeutic IndexTherapeutic UsesToxic effectUp-RegulationWorkYeastsbcl-1 Genescytotoxicdesigndrug modificationdrug testingexpectationgene inductionhigh-throughput drug screeningin vivoinhibitor/antagonistknock-downmTOR Inhibitormetabolic profilemolecular targeted therapiesnegative affectnovel therapeuticspreventprotein expressionresponseside effectsynergismtherapeutic targettumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Preliminary work indicates the mTOR-binding protein DEPTOR is a potential molecular target for therapy in
multiple myeloma. It is specifically upregulated in this disease and its silencing is lethal to myeloma cells. We,
thus, identified a potential DEPTOR inhibitor in a high-throughput drug screen. The inhibitor is effective in
myeloma cells with the expected molecular alterations and induction of death. In this proposal we plan to
further develop this inhibitor. We will generate biochemical derivatives with the aim of enhancing the
therapeutic index of DEPTOR inhibitors, identify the mechanism of action of where the inhibitors first bind in
myeloma cells, ascertain possible toxicity to normal tissues in mice with deleted DEPTOR expression and
assess possible interactions with other anti-myeloma therapeutics that are used in the clinic. Our expectation is
that these new drugs will be important additions to the armamentarium used in myeloma patients and,
furthermore, they will be specifically tailored to patients with tumors that have high DEPTOR expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of c-myc translation by hnRNP A1: Role in multiple myeloma tumor responses
-
批准号:9884542
-
项目类别:
-
资助金额:$28.82万
-
财政年份:2017
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting DEPTOR in multiple myeloma
-
批准号:10219172
-
项目类别:
-
资助金额:$28.82万
-
财政年份:2017
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Regulation of c-myc translation by hnRNP A1: Role in multiple myeloma tumor responses
-
批准号:9277218
-
项目类别:
-
资助金额:$30.87万
-
财政年份:2017
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting DEPTOR in multiple myeloma
-
批准号:8442174
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2013
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting DEPTOR in multiple myeloma
-
批准号:8601298
-
项目类别:
-
资助金额:$16.88万
-
财政年份:2013
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting TORC2 in Multiple Myeloma
-
批准号:8762435
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting TORC2 in Multiple Myeloma
-
批准号:8330231
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting of DEPTOR in Multiple Myeloma
-
批准号:9335141
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting TORC2 in Multiple Myeloma
-
批准号:8597941
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Targeting TORC2 in Multiple Myeloma
-
批准号:8963450
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Use of CCI-779 in multiple myeloma
-
批准号:7666888
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2008
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Use of CCI-779 in multiple myeloma
-
批准号:7382380
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2008
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Sensitivity Multiple Myeloma Cells to mTOR Inhibitors
-
批准号:7068601
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Sensitivity of multiple myeloma cells to mTOR inhibitors
-
批准号:8857105
-
项目类别:
-
资助金额:$18.43万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
EBV lytic re-activation in nasopharyngeal carcinoma
-
批准号:7070509
-
项目类别:
-
资助金额:$26.3万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
EBV lytic re-activation in nasopharyngeal carcinoma
-
批准号:6936975
-
项目类别:
-
资助金额:$27.99万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Sensitivity of multiple myeloma cells to mTOR inhibitors
-
批准号:8284978
-
项目类别:
-
资助金额:$18.43万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Sensitivity Multiple Myeloma Cells to mTOR Inhibitors
-
批准号:7591111
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Sensitivity Multiple Myeloma Cells to mTOR Inhibitors
-
批准号:7408112
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
Sensitivity of multiple myeloma cells to mTOR inhibitors
-
批准号:8484360
-
项目类别:
-
资助金额:$17.32万
-
财政年份:2005
-
负责人:ALAN K LICHTENSTEIN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: